← Leaderboards
Karen Ellen Wickersham
University Of Pittsburgh At Pittsburgh
$242,480
Attributed
$242,480
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $55.9K · FY2009–16$100K$75K$50K$25K$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$242,480 · 2
By mechanism
F31$124,356 · 1
F32$118,124 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Michael S. Diamond$85,358,908
- Jill M Siegfried$10,296,579
- Joanne L. Flynn$43,717,509
- Dong Moon Shin$11,702,631
- Oscar L. Lopez$26,660,804
Others in their field
Top investigators on “Non-Small-Cell Lung Carcinoma”
- Walter John Curran · Thomas Jefferson University$26,641,549
- Pasi A Janne · Stanford University$23,565,845
- Kwok Kin Wong · New York University School Of Medicine$17,033,021
- Trever G Bivona · University Of California, San Francisco$12,986,639
- Reuben J Shaw · Salk Institute For Biological Studies$11,952,012
- Matthew L Meyerson · Brigham And Women'S Hospital$11,175,304
Research focus
Non-Small-Cell Lung CarcinomaMalignant NeoplasmsErlotinibPharmaceutical PreparationsSymptomsBaseDoseEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorPathway InteractionsOralQuality Of LifeSeveritiesAdverse EffectsTumorAffectCancer PatientCancer TherapyEpidermal Growth Factor ReceptorMalignant Neoplasm Of LungLearningTyrosine Kinase InhibitorHealthcareCancer CellCancer Care
Grant awards (6)
Genetic, Clinical, and Biological Correlates of EGFR Inhibitor-related Rash$8,550
F32 · FY2016 · NR · contact PI
Genetic, Clinical, and Biological Correlates of EGFR Inhibitor-related Rash$55,860
F32 · FY2015 · NR · contact PI
Genetic, Clinical, and Biological Correlates of EGFR Inhibitor-related Rash$53,714
F32 · FY2013 · NR · contact PI
A Study of Medication Taking for NSCLC Patients Receiving Oral Targeted Therapy$41,800
F31 · FY2011 · NR · contact PI
A Study of Medication Taking for NSCLC Patients Receiving Oral Targeted Therapy$41,380
F31 · FY2010 · NR · contact PI
A Study of Medication Taking for NSCLC Patients Receiving Oral Targeted Therapy$41,176
F31 · FY2009 · NR · contact PI